Sanford C. Bernstein set a €90.00 ($104.65) target price on Bayer (FRA:BAYN) in a research report report published on Thursday morning, Borsen Zeitung reports. The firm currently has a buy rating on the healthcare company’s stock.
A number of other research analysts have also recently issued reports on the company. Goldman Sachs Group reiterated a buy rating and issued a $70.00 target price on shares of Total in a research report on Monday, July 15th. Nord/LB reiterated a neutral rating on shares of Bayerische Motoren Werke in a research report on Tuesday, June 4th. Societe Generale set a €105.00 ($122.09) target price on Merck KGaA and gave the company a neutral rating in a research report on Wednesday, March 27th. JPMorgan Chase & Co. reiterated a sell rating and issued a $18.00 target price on shares of ABB in a research report on Monday, July 15th. Finally, HSBC set a €63.00 ($73.26) target price on Bayer and gave the company a neutral rating in a research report on Monday, July 1st. One investment analyst has rated the stock with a sell rating, eleven have issued a hold rating and twelve have assigned a buy rating to the stock. Bayer currently has a consensus rating of Hold and a consensus target price of €80.67 ($93.81).
Bayer stock opened at €59.55 ($69.24) on Thursday. Bayer has a 12-month low of €91.58 ($106.49) and a 12-month high of €123.82 ($143.98). The company has a 50-day simple moving average of €56.65.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. It operates through Pharmaceuticals, Consumer Health, Crop Science, and Animal Health segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Featured Story: Market Capitalization in the Stock Market
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.